MediPharm Labs bullish on new contract.

230
MediPharm Labs' (OTCQX:MEDIF) Australian subsidiary has entered a private label sales and manufacturing agreement with a Licensed Producer in Australia and taken other important steps to advance its early leadership in the Australian and Asia-Pacific extraction market.
Under the terms of the manufacturing agreement, MediPharm Labs Australia will purchase dried flower and sell high quality, private-label cannabis oil and manufactured products. The agreement has a 12-month term with options to extend.
MediPharm Labs Australia has also successfully negotiated multi-year supply agreements with three Australian Office of Drug Control approved cultivators.
Source Seeking Alpha

COMPANY PROFILE
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon in 2015 and is headquartered in Barrie, Canada.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.